Article thumbnail

Spotlight on fevipriprant and its potential in the treatment of asthma: evidence to date

By Kao CC and Parulekar AD

Abstract

Christina C Kao, Amit D Parulekar Section of Pulmonary, Critical Care, and Sleep, Department of Medicine, Baylor College of Medicine, Houston, TX, USA Abstract: Asthma is a heterogeneous disease, which may be classified into phenotypes and endotypes based on clinical characteristics and molecular mechanisms. The best described endotype of severe asthma is type 2 (T2)-high asthma, characterized by release of inflammatory cytokines by T helper 2 (TH2) cells and type 2 innate lymphoid cells cells. Prostaglandin D2 contributes to T2 inflammation through binding of the G-protein-coupled receptor chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Fevipriprant is an oral competitive antagonist of CRTH2. Early-phase trials have demonstrated safety and potential efficacy in patients with asthma, specifically, improvement in FEV1 and eosinophilic airway inflammation. However, no clear biomarker identified patients who responded favorably to fevipriprant, although patients with moderate-to-severe asthma and evidence of T2 inflammation may be more likely to respond to treatment. Additional studies are needed to determine the efficacy and target population for use of this drug in patients with asthma. Keywords: prostaglandin D2, CRTH2, biologic

Topics: Prostaglandin D2, CRTH2, biologics, Immunologic diseases. Allergy, RC581-607
Publisher: Dove Medical Press
Year: 2019
OAI identifier: oai:doaj.org/article:ebc6c30722f94590a1fdaf1816300dbd
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/article/ebc6c... (external link)
  • https://doaj.org/toc/1178-6965 (external link)
  • https://www.dovepress.com/spot... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.